AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ESOMEPRAZOLE & DOMPERIDONE

9 registrations across 4 African markets— 7 active

Markets with ESOMEPRAZOLE & DOMPERIDONE

Recent registrations

Brand / ProductMarketHolderStatusExpires
Esofag D Capsules**
Capsule
🇳🇬NigeriaMicro Nova Pharmaceuticals Ind LtdactiveApr 2028
Kesprid Tablet
Tablet
🇳🇬NigeriaKayhelt Pharma LimitedactiveDec 2026
NEUESOME-D 40MG CAPSULE BOITE DE 30🇨🇮Côte d'IvoireAHAAN HEALTHCARE PVT LTDactiveAug 2026
ESOFAG_D 40/30MG CAPSULE
CAPSULE
🇲🇼MalawiexpiredMar 2025
NO-REFLUX 40MG/30MG GELULE BOITE DE 20🇨🇮Côte d'IvoirePRODIPHARMexpiredJan 2021
S-DOM
gélule / 40 mg /30 mg
🇸🇳SenegalAURA LIFECARE PVT LTDactive
ESOREZ-D 40MG/10MG GELULE BOITE DE 30🇨🇮Côte d'IvoireZRENIE HEALTHCARE PVT LTDactive
NEUESOME D
gélule / 40 mg / 30 mg
🇸🇳SenegalAHAAN HEALTHCARE PVT LTDactive
NEUESOME D
gélule / 40 mg / 30 mg
🇸🇳SenegalAHAAN HEALTHCARE PVT LTDactive

ESOMEPRAZOLE & DOMPERIDONE in Africa — Regulatory Overview

ESOMEPRAZOLE & DOMPERIDONE is registered across 4 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Côte d'Ivoire, Senegal, Nigeria, Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 7 (78%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.